rimegepant sulfate

structure in first source

Also Known As:

(5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta(b)pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo(4,5-b)pyridin-1-yl)piperidine-1-carboxylate; BMS-927711; Nurtec ODT; rimegepant

Networked: 103 relevant articles (21 outcomes, 39 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - rimegepant sulfate: 103
  - Piperidines: 17
    - rimegepant sulfate: 103

Experts

1.	Croop, Robert: 12 articles (01/2022 - 01/2019)
2.	Coric, Vladimir: 11 articles (01/2022 - 01/2019)
3.	Goadsby, Peter J: 8 articles (01/2021 - 02/2014)
4.	Stock, David A: 7 articles (01/2022 - 01/2019)
5.	Lipton, Richard B: 7 articles (10/2021 - 01/2019)
6.	Conway, Charles M: 5 articles (01/2021 - 01/2019)
7.	Harris, Linda: 4 articles (01/2022 - 01/2021)
8.	L'Italien, Gilbert: 4 articles (01/2022 - 01/2021)
9.	Popoff, Evan: 4 articles (01/2022 - 01/2021)
10.	Johnston, Karissa: 3 articles (01/2022 - 01/2021)

Related Diseases

1.	Migraine Disorders (Migraine) 01/01/2023 - "Among adults living in China or South Korea, a single dose of 75 mg rimegepant was effective for the acute treatment of migraine. " 02/23/2021 - "Oral Rimegepant Safe, Effective for Migraine Prevention." 01/01/2021 - "Taken every other day, rimegepant was effective for preventive treatment of migraine. " 11/01/2023 - "Rimegepant may be effective and safe for the treatment of migraine patients." 11/01/2023 - "We have searched several databases including PubMed, Embase, Web of Science, EBSCO, and Cochrane Library databases and selected the randomized controlled trials comparing the efficacy of rimegepant versus placebo for migraine patients. "
2.	Pain (Aches) 01/01/2021 - "According to data from 3 phase 3 randomized controlled trials, rimegepant has been shown to significantly improve freedom from pain at 2 hours after the dose and freedom from the most bothersome symptom 2 hours postdose. " 01/01/2023 - "2 h after dosing, rimegepant was superior to placebo for pain freedom (132 [20%] of 666 vs 72 [11%] of 674, risk difference 9·2, 95% CI 5·4-13·0; p<0·0001) and freedom from the most bothersome symptom (336 [50%] of 666 participants vs 241 [36%] of 674 participants, 14·8, 9·6-20·0; p<0·0001). " 06/01/2021 - "Expert opinion Rimegepant seems to be well tolerated and superior to placebo for two-hour pain freedom. " 11/01/2019 - "The primary end points were freedom from pain and freedom from the most bothersome symptom (other than pain) identified by the patient, both of which were assessed 2 hours after the dose of rimegepant or placebo was administered. " 01/01/2019 - "We found that 75 mg rimegepant led to significant freedom from pain (P < 0.001), pain relief (P < 0.001), and freedom from the most bothersome symptom (P < 0.001) at 2 hr post dose compared with the placebo. "
3.	Prescription Drug Overuse 10/01/2023 - "Two randomized controlled trials (RCTs) have shown promising results for rimegepant and atogepant as preventive treatments for CM. In an RCT targeting patients with CM, atogepant demonstrated a significant reduction in the mean monthly migraine days, irrespective of acute medication overuse. "
4.	Headache (Headaches) 02/01/2023 - "We present a case series of three patients with CH who reported varying degrees of decreased headache intensity after using rimegepant." 09/04/2021 - "Rimegepant is a new medicine developed for the management of chronic headache due to migraine. " 01/01/2023 - "All medications significantly reduced mean monthly headache days, although no data for this outcome was available for rimegepant, and mean monthly acute medication days, with no data for eptinezumab. " 01/01/2021 - "Methods: We updated a list of acute medications based on the widely used Jefferson Headache Manual with novel abortive medications including ubrogepant, lasmiditan, and rimegepant. " 05/11/2021 - "Acute treatments with gepants, antagonists to receptors for the inflammatory neuropeptide calcitonin gene-related peptide, such as rimegepant or ubrogepant, can eliminate headache symptoms for 2 hours in 20% of patients but have adverse effects of nausea and dry mouth in 1% to 4% of patients. "
5.	Drug-Related Side Effects and Adverse Reactions 01/01/2023 - "This study aimed at providing pooled estimates of the incidence of adverse drug reactions (ADRs) of ubrogepant and rimegepant and to use meta-regression to identify correlations between the occurrence of selected ADRs, socio-demographic, and clinical characteristics from data published in clinical studies. "

Related Drugs and Biologics

1.	Calcitonin Gene-Related Peptide Receptor Antagonists
2.	ubrogepant
3.	atogepant
4.	Calcitonin Gene-Related Peptide
5.	Tablets
6.	galcanezumab
7.	erenumab
8.	lasmiditan
9.	fremanezumab
10.	eptinezumab

Related Therapies and Procedures

1.	Therapeutics
2.	Injections
3.	Oral Administration